# Price T Rowe Group Inc: financial statements, quarterly

TROW · Nasdaq · CIK 1113169 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/trow.md) · [Financials](/companies/trow/financials.md) · [Filings](/companies/trow/filings.md) · [Insiders](/companies/trow/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/trow/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,642 d](/filings/0001628280-26-008002.md) | [1,750](/filings/0001113169-25-000015.md) | [1,733](/filings/0001113169-25-000023.md) | [1,786](/filings/0001628280-25-047751.md) | [1,825 d](/filings/0001628280-26-008002.md) | [1,764](/filings/0001628280-26-028712.md) | [1,723](/filings/0001628280-26-051335.md) | [1,894](/filings/0001113169-26-000005.md) | [1,934 d](/filings/0001628280-26-008002.md) | [1,857](/filings/0001628280-26-028712.md) | [1,907](/filings/0001628280-26-051335.md) | [2,005](/filings/0001113169-26-000005.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [387 d](/filings/0001628280-26-008002.md) | [587](/filings/0001113169-25-000015.md) | [565](/filings/0001113169-25-000023.md) | [614](/filings/0001628280-25-047751.md) | [568 d](/filings/0001628280-26-008002.md) | [596](/filings/0001628280-26-028712.md) | [478](/filings/0001628280-26-051335.md) | [643](/filings/0001113169-26-000005.md) | [471 d](/filings/0001628280-26-008002.md) | [681](/filings/0001628280-26-028712.md) | [541](/filings/0001628280-26-051335.md) | [770](/filings/0001113169-26-000005.md) |
| Income tax | $m | [173 d](/filings/0001628280-26-008002.md) | [182](/filings/0001113169-25-000015.md) | [160](/filings/0001113169-25-000023.md) | [186](/filings/0001628280-25-047751.md) | [156 d](/filings/0001628280-26-008002.md) | [162](/filings/0001628280-26-028712.md) | [158](/filings/0001628280-26-051335.md) | [195](/filings/0001113169-26-000005.md) | [153 d](/filings/0001628280-26-008002.md) | [148](/filings/0001628280-26-028712.md) | [214](/filings/0001628280-26-051335.md) | [190](/filings/0001113169-26-000005.md) |
| Net income | $m | [438 d](/filings/0001628280-26-008002.md) | [574](/filings/0001113169-25-000015.md) | [483](/filings/0001113169-25-000023.md) | [603](/filings/0001628280-25-047751.md) | [440 d](/filings/0001628280-26-008002.md) | [491](/filings/0001628280-26-028712.md) | [505](/filings/0001628280-26-051335.md) | [646](/filings/0001113169-26-000005.md) | [445 d](/filings/0001628280-26-008002.md) | [498](/filings/0001628280-26-028712.md) | [632](/filings/0001628280-26-051335.md) | [612](/filings/0001113169-26-000005.md) |
| Diluted EPS | $ per share | not reported | [2.49](/filings/0001113169-25-000015.md) | [2.11](/filings/0001113169-25-000023.md) | [2.64](/filings/0001628280-25-047751.md) | not reported | [2.15](/filings/0001628280-26-028712.md) | [2.24](/filings/0001628280-26-051335.md) | [2.87](/filings/0001113169-26-000005.md) | not reported | [2.23](/filings/0001628280-26-028712.md) | [2.88](/filings/0001628280-26-051335.md) | [2.79](/filings/0001113169-26-000005.md) |
| Basic EPS | $ per share | not reported | [2.50](/filings/0001113169-25-000015.md) | [2.11](/filings/0001113169-25-000023.md) | [2.64](/filings/0001628280-25-047751.md) | not reported | [2.15](/filings/0001628280-26-028712.md) | [2.24](/filings/0001628280-26-051335.md) | [2.88](/filings/0001113169-26-000005.md) | not reported | [2.23](/filings/0001628280-26-028712.md) | [2.88](/filings/0001628280-26-051335.md) | [2.79](/filings/0001113169-26-000005.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Gross profit: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [2.1](/filings/0001113169-25-000007.md) | [2.4](/filings/0001113169-24-000013.md) | [2.7](/filings/0001113169-24-000019.md) | [3.2](/filings/0001113169-24-000030.md) | [2.6](/filings/0001628280-26-008002.md) | [2.8](/filings/0001113169-25-000015.md) | [3.1](/filings/0001113169-25-000023.md) | [3.6](/filings/0001628280-25-047751.md) | [3.4](/filings/0001113169-26-000005.md) | [3.7](/filings/0001628280-26-028712.md) | [3.2](/filings/0001628280-26-051335.md) | [3.8](/filings/0001113169-26-000005.md) |
| Total assets | $bn | [12.3](/filings/0001113169-25-000007.md) | [12.9](/filings/0001113169-24-000013.md) | [13.1](/filings/0001113169-24-000019.md) | [13.7](/filings/0001113169-24-000030.md) | [13.5](/filings/0001628280-26-008002.md) | [14.0](/filings/0001113169-25-000015.md) | [14.3](/filings/0001113169-25-000023.md) | [14.7](/filings/0001628280-25-047751.md) | [14.3](/filings/0001113169-26-000005.md) | [14.4](/filings/0001628280-26-028712.md) | [15.4](/filings/0001628280-26-051335.md) | [16.1](/filings/0001113169-26-000005.md) |
| Total liabilities | $bn | [2.0](/filings/0001113169-25-000007.md) | [2.2](/filings/0001113169-24-000013.md) | [2.3](/filings/0001113169-24-000019.md) | [2.5](/filings/0001113169-24-000030.md) | [2.0](/filings/0001628280-26-008002.md) | [2.5](/filings/0001113169-25-000015.md) | [2.5](/filings/0001113169-25-000023.md) | [2.8](/filings/0001628280-25-047751.md) | [2.3](/filings/0001113169-26-000005.md) | [2.5](/filings/0001628280-26-028712.md) | [3.2](/filings/0001628280-26-051335.md) | [3.5](/filings/0001113169-26-000005.md) |
| Shareholders' equity | $bn | [9.5](/filings/0001113169-25-000007.md) | [9.8](/filings/0001113169-24-000013.md) | [9.9](/filings/0001113169-24-000019.md) | [10.2](/filings/0001113169-24-000030.md) | [10.3](/filings/0001628280-26-008002.md) | [10.4](/filings/0001113169-25-000015.md) | [10.6](/filings/0001113169-25-000023.md) | [10.8](/filings/0001628280-25-047751.md) | [10.9](/filings/0001113169-26-000005.md) | [10.8](/filings/0001628280-26-028712.md) | [11.0](/filings/0001628280-26-051335.md) | [11.4](/filings/0001113169-26-000005.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(157) d](/filings/0001628280-26-008002.md) | [637](/filings/0001113169-25-000015.md) | [678 d](/filings/0001113169-25-000023.md) | [653 d](/filings/0001628280-25-047751.md) | [(282) d](/filings/0001628280-26-008002.md) | [633](/filings/0001628280-26-028712.md) | [530 d](/filings/0001628280-26-051335.md) | [609 d](/filings/0001113169-26-000005.md) | [(18.7) d](/filings/0001628280-26-008002.md) | [824](/filings/0001628280-26-028712.md) | [517 d](/filings/0001628280-26-051335.md) | [543 d](/filings/0001113169-26-000005.md) |
| Capital expenditure | $m | [81.9 d](/filings/0001628280-26-008002.md) | [103](/filings/0001113169-25-000015.md) | [103 d](/filings/0001113169-25-000023.md) | [105 d](/filings/0001628280-25-047751.md) | [113 d](/filings/0001628280-26-008002.md) | [82.0](/filings/0001628280-26-028712.md) | [62.2 d](/filings/0001628280-26-051335.md) | [63.3 d](/filings/0001113169-26-000005.md) | [66.7 d](/filings/0001628280-26-008002.md) | [62.0](/filings/0001628280-26-028712.md) | [66.4 d](/filings/0001628280-26-051335.md) | [72.7 d](/filings/0001113169-26-000005.md) |
| Dividends paid | $m | [280 d](/filings/0001628280-26-008002.md) | [287](/filings/0001113169-25-000015.md) | [283 d](/filings/0001113169-25-000023.md) | [281 d](/filings/0001628280-25-047751.md) | [285 d](/filings/0001628280-26-008002.md) | [290](/filings/0001628280-26-028712.md) | [286 d](/filings/0001628280-26-051335.md) | [283 d](/filings/0001113169-26-000005.md) | [285 d](/filings/0001628280-26-008002.md) | [289](/filings/0001628280-26-028712.md) | [282 d](/filings/0001628280-26-051335.md) | [285 d](/filings/0001113169-26-000005.md) |
| Share repurchases | $m | [113 d](/filings/0001628280-26-008002.md) | [83.1](/filings/0001113169-25-000015.md) | [112 d](/filings/0001113169-25-000023.md) | [73.6 d](/filings/0001628280-25-047751.md) | [68.1 d](/filings/0001628280-26-008002.md) | [215](/filings/0001628280-26-028712.md) | [113 d](/filings/0001628280-26-051335.md) | [154 d](/filings/0001113169-26-000005.md) | [139 d](/filings/0001628280-26-008002.md) | [334](/filings/0001628280-26-028712.md) | [167 d](/filings/0001628280-26-051335.md) | [0.1 d](/filings/0001113169-26-000005.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [225](/filings/0001113169-24-000013.md) | [225](/filings/0001113169-24-000019.md) | [225](/filings/0001113169-24-000030.md) | [224](/filings/0001113169-25-000015.md) | [224](/filings/0001113169-25-000023.md) | [223](/filings/0001628280-25-047751.md) | [223](/filings/0001628280-26-028712.md) | [220](/filings/0001628280-26-051335.md) | [220](/filings/0001113169-26-000005.md) | [218](/filings/0001628280-26-028712.md) | [214](/filings/0001628280-26-051335.md) | [214](/filings/0001113169-26-000005.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 213,325,929 at 2026-10-27, from the cover of the [10-Q filed 2026-10-29](/filings/0001113169-26-000005.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 14:06 ET. No prices; not investment advice.